skip to primary navigationskip to content

The Milner Therapeutics Institute

Department A-Z

 

The Milner Therapeutics Institute is a global therapeutic alliance based in Cambridge, dedicated to the conversion of basic science into therapies. Its mission is to foster close collaborative interactions between academia and industry to accelerate medical advancement. The Institute represents a new 'open borders' paradigm, with no physical boundaries and a flexible operational model.

Read more

The Milner Therapeutics Consortium is an academic/industry partnership hosted by the Institute and is part of its outreach programme. The Consortium has been active since June 2015 and is based on a research agreement signed by three Cambridge academic centres (the University of Cambridge, the Sanger Institute and the Babraham Institute (and four pharmaceutical companies (Astex, AstraZeneca, GlaxoSmithKline and Shionogi).

Read more

The Affiliated Partners programme is composed of companies, such as service and product providers, that are developing tools to advance therapeutic needs. The Institute coordinates interactions between affiliated companies and academic, pharmaceutical or biotechnology partners, with the aim of making a cohesive therapeutically mixed community. Affiliation to the Institute provides networking and advertising opportunities and fast exchange of information and know-how. There are currently 29 Affiliated Partners.

Read more

The Institute will have research laboratories within the new Capella Building on the Cambridge Biomedical Campus. The laboratories will be operational in 2018 and will house research groups from the Cambridge research community. A research facility will also be established, accessible to the wider research community as part of the outreach programme. The facility is envisaged to house robotics for customised drug screening as well as gene editing and bioinformatics support.

Shionogi Innovation Competition

Applications are currently being invited to the Shionogi Science Program. For scientific areas of interest please read more. Deadline 24th February 2017.

Read more

New partnership with Pfizer

Press Release Cambridge, 19 January 2017 – The Milner Therapeutics Institute announces Pfizer as a new partner joining the Consortium to develop mutually-beneficial collaborations with Cambridge academics and the Milner Therapeutics Institute.

Read more

Milner Therapeutics Symposium 17 Nov 2016

The inaugural Milner Therapeutics Symposium was an opportunity for scientists from academia and industry to discuss the latest research in Cambridge and how it could be applied in the pharma and biotech industry to develop new treatments. The Symposium brochure can be downloaded here and contains abstracts from the speakers and the poster session. There is also a short introduction and contact details for all the Milner Affiliated companies, as well some photographs from the day.

Read more

University of Cambridge/Charles River Roadshow

Scientists from throughout Cambridge University attended a roadshow supported by Charles River Laboratories to discuss projects that may have drug discovery potential. Click here to see the programme and some pictures from the event. The roadshow was a collaboration between Charles River Laboratories, the Milner Therapeutics Institute, the Office of Translational Research and the Bioscience Impact Team.

Read more


Previous talks in Cambridge

Prof Tony Kouzarides gave a series of short talks around Cambridge to highlight opportunities for academics to collaborate with pharmaceutical and biotech companies, facilitated by the Milner Institute. For details of previous talks, please click here.

Read more

New partnership with Shionogi

Press Release Cambridge, 13 June 2016 – The Milner Therapeutics Institute announces Shionogi as a new partner joining the consortium. This represents Shionogi’s first research consortium outside Japan and their first major research investment in the UK.

Read more

Milner Therapeutics Institute & Consortium Launch Event - 14th March 2016

Pharmaceutical companies and academics gathered over dinner at Jesus College to launch the Milner Therapeutics Institute and Consortium, run by the Gurdon Institute's Tony Kouzarides. The Consortium is already working to match-make between academics and industry colleagues to collaborate on researching new medicines.

Read more

Press release - 28 Jul 2015

An innovative new Consortium will act as a ‘match-making’ service between pharmaceutical companies and researchers in Cambridge with the aim of developing and studying precision medicines for some of the most globally devastating diseases.

Read more

 

       

 

 

 

       

 

 

 

 

 

 

 

  

 

 

 

 

 

 

 

 

 

 

 

 

 

        See Affiliated Companies